At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
TPIV200 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating TPIV200 and Durvalumab for Ovarian Cancer. Completed, enrolled 29 participants across 5 sites.
Detailed Summary
This is a Phase 2 clinical trial, which tests two investigational drugs: TPIV200/huFR-1 (also called TPIV200), which is a vaccine consisting of proteins from the folate receptor alpha mixed with GM-CSF, and durvalumab (MEDI4736) , which is an antibody drug that help un-block parts of the immune system. The aim of this study is to find out whether these drugs, when given together are safe, and whether they are effective in treating cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesUnited States
CollaboratorsAstraZeneca, Marker Therapeutics, Inc.
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartMay 2016
Primary CompletionJan 2021
TodayJul 2026
First PostedMay 6, 2016
Enrollment StartMay 6, 2016
Primary CompletionJan 20, 2021
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 10.2 years ago
Interventions
TPIV200biological
Durvalumabbiological